ELVN Enliven Therapeutics, Inc.
USHealthcareAs of 2026-07-10 13:53
Why ELVN matters now
Enliven Therapeutics, Inc. (ELVN) is a US stock in Healthcare. The latest InvestLog snapshot shows $51.01 with -2.24% on the session and $3.64B in market capitalization; recent performance reads 1-month +12.27% and YTD +192.86%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.6M, and EPS of $-0.38. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.4%.
The latest indexable market news headline is "What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $61.00; recent insider activity includes ORBIMED ADVISORS LLC filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.25
P/S
0.00
EV/EBITDA
-26.53
DCF Value
$1.70
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-21.0%
ROA
-21.2%
ROIC
-25.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.6M | $-0.38 |
| Q4 2025 | $0.00 | $-29.7M | $-0.45 |
| FY 2025 | $0.00 | $-103.7M | $-1.83 |
| Q3 2025 | $0.00 | $-20.1M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$65.25
Target (Median)
$61.00
Target Range
$59.00 - $80.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.40
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.